Quizartinib (AC220) 是一种具有口服活性的、高选择性的，有效的第二代 Ⅱ 型 FLT3 (type II FLT3) 酪氨酸激酶抑制剂，Kd 值为 1.6 nM。Quizartinib 抑制 Wt FLT3 和 突变型 FLT3-ITD 自磷酸化，IC50 分别为 4.1 nM 和 1.1 nM。Quizartinib 可以通过优化的 linker 与 VHL 配体连接，从而形成 PROTAC Flt3 降解剂。Quizartinib 诱导细胞凋亡 (apoptosis)。
| CAS No. | 950769-58-1 |
| 生物活性 | Quizartinib (AC220) is an orally active, highly selective and potent second-generation type II FLT3 tyrosine kinase inhibitor, with a Kd of 1.6 nM. Quizartinib inhibits wild-type FLT3 and FLT3-ITD autophosphorylation in MV4-11 cells with IC50s of 4.2 and 1.1 nM, respectively. Quizartinib can be linked to the VHL ligand via an optimized linker to form a PROTAC FLT3 degrader. Quizartinib induces apoptosis. |
| 分子式 | C29H32N6O4S |
| 分子量 | 560.67 |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存条件 | Powder -20°C 3 years |
| 溶解性数据 | DMSO : ≥ 33 mg/mL (58.86 mM) |
| 体内研究 | Quizartinib (AC220) inhibits FLT3 activity in vivo, significantly extends survival in a mouse model of FLT3-ITD AML at doses as low as 1 mg/kg when dosed orally once a day, eradicates tumors in a FLT3-dependent mouse xenograft model at 10 mg/kg, and potently inhibits FLT3 activity in primary patient cells. The oral bioavailability of Quizartinib, determined in rats by comparing oral and intravenous pharmacokinetics at 3 mg/kg, is approximately 40%. A single 10 mg/kg dose of Quizartinib is administered by oral gavage, and mice are killed at 2 time points after dosing, using groups of 4 animals each. Quantitation of total FLT3 and phospho-FLT3 in tumor samples revealed time-dependent inhibition of FLT3 autophosphorylation. FLT3 activity is inhibited by 90% at 2 hours, and 40% at 24 hours after administration. The extent of inhibition therefore correlated well with the expected free Quizartinib plasma levels, based on pharmacokinetic experiments. |
| 体外研究 | Quizartinib (AC220) is a novel compound expressly optimized as a FLT3 inhibitor for the treatment of acute myeloid leukemia (AML). Quizartinib inhibits FLT3-WT and FLT3-ITD autophosphorylation with IC50 of 4.2±0.3 nM and 1.1±0.1 nM, respectively. Quizartinib inhibits MV4-11 and A375 cells with IC50 of 0.56±0.3 nM and >10 000 nM, respectively. Quizartinib inhibits FLT3 with low nanomolar potency in cellular assays and is highly selective when screened against the majority of the human protein kinome. |
| 文献 | •Cancer Cell. 2018 Oct 8;34(4):674-689.e8. •Cancer Cell. 2014 Feb 10;25(2):226-42. •Sci Transl Med. 2018 Jul 18;10(450). pii: eaaq1093. •Nat Commun. 2018 Jan 24;9(1):358. •Leukemia. 2012 Oct;26(10):2233-44. •Acta Pharm Sin B. 2021. Jun 16. •J Med Chem. 2021 Jul 21. •J Med Chem. 2017 Oct 26;60(20):8407-8424. •Haematologica. 2018 Nov;103(11):1862-1872. •Mol Cancer Ther. 2015 Oct;14(10):2249-59. •Mol Cancer Res. 2021 Oct 11. •Br J Haematol. 2019 Nov;187(4):488-501. •Vaccines. 2021, 9(11), 1294. •PLoS One. 2013;8(2):e56473. •Univerzita Karlova v Praz. 2021 Jul. •Faculty of Medicine, Leiden Uiversity Medical Center (LUMC), 2019 Mar. •Oncotarget. 2017 Jun 28;8(40):67639-67650. •Oncotarget. 2016 Jul 26;7(30):47018-47032. •Harvard Medical School LINCS LIBRARY |
| 纯度及产品资料 | 98% |
邮箱：info@TianyaBio.com
电话：020-3107 8154
地址：广州市番禺区兴业大道东路1078号2-50
微信公众号
微信客服
